Overview

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Status:
RECRUITING
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigational medication called niraparib is being tested for the treatment of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their genes. Cancer cells with damaged genes have a harder time growing and spreading in the body and can even die.
Phase:
PHASE4
Details
Lead Sponsor:
University of Miami
Collaborator:
GlaxoSmithKline
Treatments:
niraparib